【摘要】 目的观察脑梗死患者用拜阿司匹灵治疗前、后血浆血小板4因子(PF4)的变化。方法70例脑梗死患者被随机分为不用拜阿司匹灵组(n=40)和服用拜阿司匹灵组(100mg/次,睡前服用,n=30),其他治疗两组间无差异。用酶标免疫测定法测定二组治疗前、治疗后7d及30例正常对照组血浆PF4的含量。结果急性脑梗死不用拜阿司匹灵组的患者血浆PF4治疗前为15.12±6.32ng/ml,治疗后为9.83±4.93ng/ml,治疗后PF4的明显下降(P<0.01),但显著高于正常对照组(6.50±2.70ng/ml,P<0.01);服用拜阿司匹灵组的患者血浆PF4治疗前为15.48±3.16ng/ml,治疗7d后为7.66±1.47ng/ml,较治疗前明显下降(P<0.01),也明显低于不用拜阿司匹灵组的患者(P<0.01),但仍高于正常对照组(6.50±2.70ng/ml,P<0.05)。结论拜阿司匹灵能降低脑梗死患者血浆PF4含量水平,抑制血小板活性。更多还原

【Abstract】 Objective To observe the changes of plasma platelet factor 4 (PF4) in patients with cerebral infarction before and after Bayaspirin treatment.Methods Seventy patients with cerebral infarction were randomly divided into 2 groups: Bayaspirin-treated group (n=30) and control group without Bayaspirin treatment (n=40). The content of plasma PF4 was measured by ELISA before treatment and on the 7th day after treatment. Thirty healthy people served as the normal control group.Results The plasma PF4 levels in the patient control group without Bayaspirin treatment before treatment was 15.12±6.32 ng/ml and decreased after conventional treatment (9.83±4.93 ng/ml) (P<0.01), but were significantly higher than in the healthy control group (6.50±2.70 ng/ml) (P<0.01). The plasma PF4 levels in the Bayaspirin-treated group decreased significantly after Bayaspirin together with conventional treatment compared with before treatment (7.66±1.47 ng/ml vs 15.48±3.16 ng/ml; P<0.01) and were also lower than in the patient control group without Bayaspirin treatment (P<0.01), although were higher than in the healthy control group (P<0.05).Conclusions Bayaspirin can reduce plasma PF4 levels and inhibit the platelet activity in patients with cerebral infarction.更多还原